Epidemiological characteristics of patients with COVID-19 in Southwest of Iran from February 19 to June 20, 2020

Azarbakhsh, Habibollah; Jokari, Kimia; Moftakhar, Leila; Ghelichi-Ghojogh, Mousa; Karimyan, Azimeh; Salmanzadeh, Shokrollah; Zeitooni, Mehrdad Parian; Khezri, Rozhan; Valipour, Aliasghar

doi:10.47176/mjiri.35.116

Cited by 10 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This might be because of the higher age of regular COVID-19 during the study period of time in our center. The mean age of COVID-19 patients varies in a wide range, while in a study with more than 7 thousand COVID-19 patients in Iran, the mean age of infection was reported as 41.48 ± 16.35 [ 25 ]. According to the same meta-analysis [ 24 ], the male gender is commonly affected by CAM; we observed a higher number of males than controls (63.5% vs. 53.1), but not in a statistically significant manner in comparison to the regular included COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

“…Random selection of COVID-19 patients has been done in only surviving patients, because one of our goals was to identify risk factors for the development of CAM, and we needed to have at least three months of follow-up of patients to make sure that CAM has not happened. Thus, we were unable to compare the mortality rate between COVID-19 alone and CAM; according to the literature, the mortality for COVID-19 in Iran is ~ 5% [ 25 ]. Additionally, only the inclusion of surviving patients might affect the accuracy of some reported markers which are associated with CAM development, since some of these factors might be associated with mortality.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study

et al. 2022

View full text Add to dashboard Cite

Background COVID-19 associated mucormycosis (CAM) has been known as one of the most severe post-COVID morbidities. Objectives To describe CAM cases, identify possible risk factors, and report outcomes of patients. Methods This retrospective study was performed in Amir-Alam Hospital, Tehran, Iran between February 2020 and September 2021. Patients with mucormycosis who had an active or previous diagnosis of COVID-19 have been included. Results Of 94 patients with mucormycosis, 52 (33 men and 19 women; mean age: 57.0 ± 11.82 years) were identified with an active or history of COVID-19. Rhino-orbital, rhino maxillary, rhino-orbito cerebral subtypes of mucormycosis were detected in 6 (11.5%), 18(34.6%), and 28(53.8%) patients. As a control group, 130 (69 men and 61 women; mean age: 53.10 ± 14.49 years) random RT-PCR-confirmed COVID-19 patients without mucormycosis have been included. The mean interval between COVID-19 diagnosis and initial mucormycosis symptoms was 16.63 ± 8.4 days (range 0–51). Those in the CAM group had a significantly more severe course of COVID-19 (OR = 3.60, P -value < 0.01). Known history of previous diabetes mellitus (OR = 7.37, P -value < 0.01), smoking (OR = 4.55, P -value < 0.01), and history of receiving high-dose corticosteroid pulse therapy because of more severe COVID-19 ( P -value = 0.022) were found as risk factors. New-onset post-COVID hyperglycemia was lower in the CAM group (46.2% vs. 63.8%; OR = 0.485, P -value = 0.028). After treatment of the CAM group, 41(78.8%) of patients recovered from mucormycosis. The mean ages of the expired patients in the CAM group were significantly higher than those who recovered from mucormycosis (66.18 ± 9.56 vs. 54.56 ± 11.22 years; P < 0.01); and COVID-19 disease was more severe ( P = 0.046). Conclusion Either active or history of COVID-19 can cause an increase in the risk of mucormycosis development. Some of the most important risk factors are the medical history of diabetes mellitus, smoking, and high-dose corticosteroid therapy. CAM is important possible comorbidity related to COVID-19, which could make the post-COVID conditions more complicated. More research and studies with greater sample sizes among different ethnicities are needed to explore the association between COVID-19 and mucormycosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, the prevalence of death from COVID-19 in this study (11.2%) was so much higher than the finding of studies from china 2.84%, 20 South Korea 1.1%, 21 and Iran 1.8%. 22 It is expected that the impact of the COVID-19 outbreak in Ethiopia is to be far reaching and more catastrophic than in high-income countries. This might be due to concurrent co-morbidity among the general population, population size, and status of health systems and health workforce, which both have low resilience to external shocks and have insufficient critical care capacities.…”

Section: Discussionmentioning

confidence: 99%

Incidence of Death and Its Predictors of COVID-19 in Amhara Region, Ethiopia: A Retrospective Follow Up Study

Dessie

Animut

Genet

et al. 2022

IDR

View full text Add to dashboard Cite

Background Risk factors associated with COVID-19 incidence of death would aid to notify the most favorable management strategies, hang about undecided, Moreover, studies regarding this issue are limited in Ethiopia and no region-wise study is conducted. Hence, the study investigated the COVID-19 incidence of death and its predictors in the Amhara regional state, Ethiopia. Methods A facility-based retrospective survey was conducted at all Amhara regional state COVID-19 treatment centers from 13 March 2020, through 13 January 2022. Epidata version 3.1 and STATA version 14 were used for data entry and analysis, respectively. Linearized survey analysis in a stratified Cox regression model was fitted to identify independent risk factors. P-value with 95% CI for hazard ratio was used for testing the significance at alpha 0.05. Results A total of 28,533 study participants were analyzed in this study. Of these, 2873 (11.2%) died and 25,660 (88.8%) were recovered from COVID-19. The death rate was 11.78 per 1000 person-days of observation with a median survival time of 32 days with IQR [12, 44]. Patients with co-morbidities (AHR = 1.54: 95% CI: 1.51–1.55), patients with age <5-year (AHR = 1.69: 95% CI: 1.78–1.81) and patients with age 60+ years (AHR = 2.91: 95% CI: 1.79–3.99), patients with asymptomatic diseases condition (AHR =1.15: 95% CI: 1.01–1.19), and being male (AHR = 1.22: 95% CI: 1.18–1.27) were independent significant risk factors of death from COVID-19. Conclusion A relatively high incidence of death from COVID-19 was found in this study. Significant risk factors were identified as patients with age <5 years, patients with age 60+ Years, being male, patients having at least one comorbid condition, and patients with asymptomatic disease conditions. These factors should be taken into consideration for a strategy of quarantining and treating COVID-19 patients.

show abstract

“…COVID-19 is more contagious than severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS) (5). The disease was first reported in Iran on February 19, and so far Iranians have experienced several waves of disease that have resulted in many deaths (6). The clinical manifestations of COVID-19 can be very different.…”

Section: Introductionmentioning

confidence: 99%

Validation of the persian version of the COVID-19 prevention, recognition and home-management self-efficacy scale

Aslani¹,

Ebadi²,

Rostami³

et al. 2022

Przegl Epidemiol

View full text Add to dashboard Cite

INTRODUCTION. Adopting preventive behaviors and following the guidelines for controlling the COVID-19 epidemic depend on people’s self-efficacy in carrying out these behaviors and instructions. The aim of this study was to investigate the psychometric properties of the Persian version of the COVID-19 Self-Efficacy Scale (COVID-19 SES, Hernández-Padilla et al., 2020). MATERIAL AND METHODS. This cross-sectional study was performed in a group of 400 people who were residents of the city of Asadabad in western Iran from December 2020 to January 2021. The participants were selected using a convenience sampling method. Face and content validity was assessed qualitatively based on feedback from the participants and experts, and the necessary changes were applied to the final version of the questionnaire. For construct validity, exploratory factor analysis (n=200) and confirmatory factor analysis (n=200) were performed. Internal consistency was expressed as Cronbach’s alpha coefficient. Relative stability was assessed using the intraclass correlation coefficient (ICC), and absolute stability was calculated through examination of standard error of measurement (SEM). RESULTS. In exploratory factor analysis, three factors of prevention, symptom recognition, and homemanagement of COVID-19 were extracted that together explained 71.35% of the total variance. The internal consistency of the whole instrument was 0.955 and its three dimensions were 0.894, 0.916 and 0.955, respectively. In addition, an ICC of 0.986 (95% CI: 0.975-0.993, p=0.001) was found. In the confirmatory factor analysis, comparative and parsimonious fit indices were excellent, and absolute fit indices were moderate. CONCLUSIONS. The Persian version of the COVID-19 SES has good validity and reliability and can be used to measure self-efficacy in prevention, symptoms recognition, and home-management of COVID-19.

show abstract

Epidemiological characteristics of patients with COVID-19 in Southwest of Iran from February 19 to June 20, 2020

Cited by 10 publications

References 17 publications

Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study

Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study

Incidence of Death and Its Predictors of COVID-19 in Amhara Region, Ethiopia: A Retrospective Follow Up Study

Validation of the persian version of the COVID-19 prevention, recognition and home-management self-efficacy scale

Contact Info

Product

Resources

About